Salarius Pharmaceuticals effects 1-for-15 reverse stock split to regain Nasdaq compliance

Decoy Therapeutics Inc.

Reverse split effective 5:00 p.m. ET on August 15, 2025; trading on split-adjusted basis from August 18, 2025.
Shares outstanding reduced from ~7.6M to ~509,000; no fractional shares, cash in lieu paid.
New CUSIP number 79400X503; authorized shares and par value unchanged.
Split approved by stockholders at July 8, 2025 special meeting; ratio set by Board.

item 3.03item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.